.Pharmacolibrary.Drugs.ATC.J.J05AJ04 .Pharmacolibrary.Drugs.ATC.J.J05AJ04| name: | Cabotegravir |
| ATC code: | J05AJ04 | route: | oral |
| n-compartments | 2 |
Cabotegravir is a long-acting integrase strand transfer inhibitor (INSTI) used for the treatment and prevention of HIV-1 infection in adults and adolescents. It is approved for use in combination with rilpivirine for both treatment and pre-exposure prophylaxis (PrEP).
Population pharmacokinetic model in healthy adults, after a single 30 mg oral dose.
Thoueille, P, et al., & Guidi, M (2024). Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV. Clinical pharmacology and therapeutics 115(6) 1450–1459. DOI:10.1002/cpt.3240 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38519844
Han, K, et al., & Ford, SL (2022). Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. British journal of clinical pharmacology 88(10) 4607–4622. DOI:10.1111/bcp.15439 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35695476
Han, K, et al., & Ford, SL (2024). Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. Antimicrobial agents and chemotherapy 68(6) e0147523–None. DOI:10.1128/aac.01475-23 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38709006